PBYI
Price
$2.90
Change
-$0.02 (-0.68%)
Updated
Feb 21 closing price
Capitalization
142.6M
4 days until earnings call
VNDA
Price
$4.43
Change
-$0.06 (-1.34%)
Updated
Feb 21 closing price
Capitalization
258.34M
66 days until earnings call
Ad is loading...

PBYI vs VNDA

Header iconPBYI vs VNDA Comparison
Open Charts PBYI vs VNDABanner chart's image
Puma Biotechnology
Price$2.90
Change-$0.02 (-0.68%)
Volume$483.64K
Capitalization142.6M
Vanda Pharmaceuticals
Price$4.43
Change-$0.06 (-1.34%)
Volume$569.32K
Capitalization258.34M
PBYI vs VNDA Comparison Chart
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PBYI vs. VNDA commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Hold and VNDA is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (PBYI: $2.90 vs. VNDA: $4.43)
Brand notoriety: PBYI and VNDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 89% vs. VNDA: 92%
Market capitalization -- PBYI: $142.6M vs. VNDA: $258.34M
PBYI [@Biotechnology] is valued at $142.6M. VNDA’s [@Biotechnology] market capitalization is $258.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green whileVNDA’s FA Score has 1 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • VNDA’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than VNDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 5 TA indicator(s) are bullish while VNDA’s TA Score has 2 bullish TA indicator(s).

  • PBYI’s TA Score: 5 bullish, 4 bearish.
  • VNDA’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than VNDA.

Price Growth

PBYI (@Biotechnology) experienced а +1.57% price change this week, while VNDA (@Biotechnology) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

PBYI is expected to report earnings on May 01, 2025.

VNDA is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VNDA($258M) has a higher market cap than PBYI($143M). VNDA has higher P/E ratio than PBYI: VNDA (126.00) vs PBYI (6.18). PBYI YTD gains are higher at: -4.754 vs. VNDA (-7.516). PBYI has higher annual earnings (EBITDA): 49.4M vs. VNDA (-30.16M). VNDA has more cash in the bank: 376M vs. PBYI (96.7M). VNDA has less debt than PBYI: VNDA (7.94M) vs PBYI (86.4M). PBYI has higher revenues than VNDA: PBYI (244M) vs VNDA (191M).
PBYIVNDAPBYI / VNDA
Capitalization143M258M55%
EBITDA49.4M-30.16M-164%
Gain YTD-4.754-7.51663%
P/E Ratio6.18126.005%
Revenue244M191M128%
Total Cash96.7M376M26%
Total Debt86.4M7.94M1,088%
FUNDAMENTALS RATINGS
PBYI vs VNDA: Fundamental Ratings
PBYI
VNDA
OUTLOOK RATING
1..100
226
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2389
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (46) in the Biotechnology industry is somewhat better than the same rating for VNDA (84). This means that PBYI’s stock grew somewhat faster than VNDA’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VNDA (100). This means that PBYI’s stock grew similarly to VNDA’s over the last 12 months.

PBYI's SMR Rating (23) in the Biotechnology industry is significantly better than the same rating for VNDA (89). This means that PBYI’s stock grew significantly faster than VNDA’s over the last 12 months.

PBYI's Price Growth Rating (60) in the Biotechnology industry is in the same range as VNDA (61). This means that PBYI’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PBYI (100). This means that VNDA’s stock grew significantly faster than PBYI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIVNDA
RSI
ODDS (%)
N/A
Bullish Trend 5 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 4 days ago
69%
Declines
ODDS (%)
Bearish Trend 16 days ago
87%
Bearish Trend 2 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TMPIX55.99N/A
N/A
Touchstone Mid Cap Institutional
BLRCX11.33N/A
N/A
Brookfield Global Listed Real Estate C
HLEZX17.61N/A
N/A
Harding Loevner Instl Emerg Mkts Z
LHCOX20.39N/A
N/A
Lord Abbett Health Care F3
JNPSX22.39-0.48
-2.10%
Janus Henderson Small Cap Value D

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with ABCL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
-0.51%
ABCL - PBYI
36%
Loosely correlated
-3.50%
MDGL - PBYI
34%
Loosely correlated
-4.22%
VRCA - PBYI
34%
Loosely correlated
-0.78%
VNDA - PBYI
33%
Loosely correlated
-1.34%
AURA - PBYI
33%
Poorly correlated
-1.57%
More

VNDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with AMLX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
-1.34%
AMLX - VNDA
42%
Loosely correlated
-6.25%
GOSS - VNDA
37%
Loosely correlated
-8.50%
IKNA - VNDA
37%
Loosely correlated
-4.14%
VCYT - VNDA
36%
Loosely correlated
-4.56%
ATRA - VNDA
34%
Loosely correlated
-5.45%
More